3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
48
Prostatic Neoplasms, Castration-Resistant
3
Adenocarcinoma
3
Urogenital Neoplasms
2
Salivary Gland Neoplasms
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Neoplasm Metastasis
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Biochemically Recurrent Prostate Cancer
2
Urogenital Diseases
1
Triple Negative Breast Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
asciminib
8
Dasatinib
7
nilotinib
6
Imatinib Mesylate
5
Cyclophosphamide
4
ponatinib
3
fludarabine phosphate
3
bosutinib
3
Whole-Body Irradiation
3
ruxolitinib
2
letermovir
2
Tacrolimus
2
Specimen Handling
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methotrexate
2
Melphalan
2
Cyclosporine
2
Busulfan
2
venetoclax
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
decitabine and cedazuridine drug combination
1
Vorinostat
1
Valganciclovir
1
Tyrosine Kinase Inhibitors
1
Therapeutics
1
Stem Cell Transplantation
1
Sirolimus
1
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Chronic-Phase
×
darolutamide
×
1 year
×
Clear all
No trials found.